Evidence map›Paper›PMID 28663312›Full record

ArticleThe Journal of pharmacology and experimental therapeutics2017

Race, Gender, and Genetic Polymorphism Contribute to Variability in Acetaminophen Pharmacokinetics, Metabolism, and Protein-Adduct Concentrations in Healthy African-American and European-American Volunteers.

Michael H Court, Zhaohui Zhu, Gina Masse, Su X Duan, Laura P James, Jerold S Harmatz, David J Greenblatt

Registry-linked trialOpen access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of pharmacology and experimental therapeutics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00768716 (Effect of Race/Ethnicity and Genes on Acetaminophen Pharmacokinetics), which is not on this map. Cited by 28 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 1 pooled it
7.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00768716 phase4completednot on this map

Effect of Race/Ethnicity and Genes on Acetaminophen Pharmacokinetics

TypeinterventionalSponsorTufts UniversityRan2008 to 2013Enrolled95ConditionsPain, Fever, HepatotoxicityArmsAcetaminophen
3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 1 synthesis or guideline pooled it, 66 citations in OpenAlex.

  1. Pooled it
  2. Curcumin enhances the oral bioavailability of testosterone by inhibiting its intestinal metabolism.Drug metabolism and disposition: the biological fate of chemicals · 2025
    Trial
  3. A Multi-Omic Mosaic Model of Acetaminophen Induced Alanine Aminotransferase Elevation.Journal of medical toxicology : official journal of the American College of Medical Toxicology · 2023
    Trial
  4. Trial
  5. A systems pharmacology model for paracetamol overdose and treatment.Journal of pharmacokinetics and pharmacodynamics · 2026
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. CommonJournal of personalized medicine · 2022
    Article
  14. Article
  15. Review
  16. Adducts Post Acetaminophen Overdose Treated with a 12-Hour vs 20-Hour Acetylcysteine Infusion.Journal of medical toxicology : official journal of the American College of Medical Toxicology · 2020
    Article
  17. Article
  18. Article
  19. Article
  20. Acetaminophen Hepatotoxicity.Seminars in liver disease · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Michael H CourtPharmacogenomics Laboratory (M.H.C., Z.Z.), Program in Individualized Medicine (PrIMe), Department of Veterinary Clinical Sciences, College of Veterinary Medicine, Washington State University, Pullman, Washington; Program in Pharmacology and Experimental Therapeutics (G.M., S.X.D., J.S.H., and D.J.G.), Tufts University School of Medicine, Boston, Massachusetts; Department of Pediatrics, University of Arkansas for Medical Sciences and Arkansas Children's Hospital Research Institute (L.P.J.), Little Rock, Arkansas michael.court@vetmed.wsu.edu.
Zhaohui ZhuPharmacogenomics Laboratory (M.H.C., Z.Z.), Program in Individualized Medicine (PrIMe), Department of Veterinary Clinical Sciences, College of Veterinary Medicine, Washington State University, Pullman, Washington; Program in Pharmacology and Experimental Therapeutics (G.M., S.X.D., J.S.H., and D.J.G.), Tufts University School of Medicine, Boston, Massachusetts; Department of Pediatrics, University of Arkansas for Medical Sciences and Arkansas Children's Hospital Research Institute (L.P.J.), Little Rock, Arkansas.
Gina MassePharmacogenomics Laboratory (M.H.C., Z.Z.), Program in Individualized Medicine (PrIMe), Department of Veterinary Clinical Sciences, College of Veterinary Medicine, Washington State University, Pullman, Washington; Program in Pharmacology and Experimental Therapeutics (G.M., S.X.D., J.S.H., and D.J.G.), Tufts University School of Medicine, Boston, Massachusetts; Department of Pediatrics, University of Arkansas for Medical Sciences and Arkansas Children's Hospital Research Institute (L.P.J.), Little Rock, Arkansas.
Su X DuanPharmacogenomics Laboratory (M.H.C., Z.Z.), Program in Individualized Medicine (PrIMe), Department of Veterinary Clinical Sciences, College of Veterinary Medicine, Washington State University, Pullman, Washington; Program in Pharmacology and Experimental Therapeutics (G.M., S.X.D., J.S.H., and D.J.G.), Tufts University School of Medicine, Boston, Massachusetts; Department of Pediatrics, University of Arkansas for Medical Sciences and Arkansas Children's Hospital Research Institute (L.P.J.), Little Rock, Arkansas.
Laura P JamesPharmacogenomics Laboratory (M.H.C., Z.Z.), Program in Individualized Medicine (PrIMe), Department of Veterinary Clinical Sciences, College of Veterinary Medicine, Washington State University, Pullman, Washington; Program in Pharmacology and Experimental Therapeutics (G.M., S.X.D., J.S.H., and D.J.G.), Tufts University School of Medicine, Boston, Massachusetts; Department of Pediatrics, University of Arkansas for Medical Sciences and Arkansas Children's Hospital Research Institute (L.P.J.), Little Rock, Arkansas.
Jerold S HarmatzPharmacogenomics Laboratory (M.H.C., Z.Z.), Program in Individualized Medicine (PrIMe), Department of Veterinary Clinical Sciences, College of Veterinary Medicine, Washington State University, Pullman, Washington; Program in Pharmacology and Experimental Therapeutics (G.M., S.X.D., J.S.H., and D.J.G.), Tufts University School of Medicine, Boston, Massachusetts; Department of Pediatrics, University of Arkansas for Medical Sciences and Arkansas Children's Hospital Research Institute (L.P.J.), Little Rock, Arkansas.
David J GreenblattPharmacogenomics Laboratory (M.H.C., Z.Z.), Program in Individualized Medicine (PrIMe), Department of Veterinary Clinical Sciences, College of Veterinary Medicine, Washington State University, Pullman, Washington; Program in Pharmacology and Experimental Therapeutics (G.M., S.X.D., J.S.H., and D.J.G.), Tufts University School of Medicine, Boston, Massachusetts; Department of Pediatrics, University of Arkansas for Medical Sciences and Arkansas Children's Hospital Research Institute (L.P.J.), Little Rock, Arkansas.
University of Arkansas for Medical Sciences · USArkansas Children's Hospital · USTufts University · USWashington State University · US

Funding

MOLECULAR DETERMINANTS OF UGT FUNCTIONR01GM061834 · NIGMS · TUFTS UNIVERSITY BOSTON · PI COURT, MICHAEL H · 2000 to 2010
$2.4M
MicroRNAs as effectors of variable human drug metabolismR01GM102130 · NIGMS · WASHINGTON STATE UNIVERSITY · PI COURT, MICHAEL H · 2012 to 2015
$1.1M
NIGMS NIH HHS R01 GM061834NIGMS NIH HHS R01 GM102130
6 · The paper itself

Abstract

Over 30 years ago, black Africans from Kenya and Ghana were shown to metabolize acetaminophen faster by glucuronidation and slower by oxidation compared with white Scottish Europeans. The objectives of this study were to determine whether similar differences exist between African-Americans and European-Americans, and to identify genetic polymorphisms that could explain these potential differences. Acetaminophen plasma pharmacokinetics and partial urinary metabolite clearances via glucuronidation, sulfation, and oxidation were determined in healthy African-Americans (18 men, 23 women) and European-Americans (34 men, 20 women) following a 1-g oral dose. There were no differences in acetaminophen total plasma, glucuronidation, or sulfation clearance values between African-Americans and European-Americans. However, median oxidation clearance was 37% lower in African-Americans versus European-Americans (0.57 versus 0.90 ml/min per kilogram;

Indexed as

Polymorphism, GeneticAcetaminophenAnalgesics, Non-NarcoticBlack or African AmericanCysteineFemaleGene FrequencyGlucuronidesGlucuronosyltransferaseHealthy VolunteersHumansMaleMetabolic Clearance RateMetabolic Detoxication, Phase IMetabolic Detoxication, Phase IIProtein BindingAcetaminophenacetaminophen cysteineAnalgesics, Non-NarcoticCysteineGlucuronidesGlucuronosyltransferaseUDP-glucuronosyltransferase 2B15, human

Identifiers

PMID28663312
PMCPMC5562097
OpenAlexW2732998799

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.